{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:10Z","timestamp":1790916790679,"version":"4.1.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":203,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101336","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:58:57Z","timestamp":1785801537000},"page":"101336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Radiotherapy strategies for prostate cancer: Techniques, outcomes, and patient care"],"prefix":"10.1016","volume":"48","author":[{"given":"Amirreza","family":"Khalaji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhood","family":"Ghazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Alivirdiloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munthar Kadhim","family":"Abosaoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar","family":"T","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhashree","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8939-3688","authenticated-orcid":false,"given":"Ahmad","family":"Mobed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10437","key":"10.1016\/j.ctarc.2026.101336_bib0001","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101336_bib0002","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.euo.2023.09.006","article-title":"Outcomes of cytoreductive radical prostatectomy for oligometastatic prostate cancer on prostate-specific membrane antigen positron emission tomography: results of a Multicenter European Study","volume":"7","author":"Rajwa","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.ctarc.2026.101336_bib0003","series-title":"Prostate Cancer Statistics","author":"Quaye","year":"2024"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101336_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.14582","article-title":"Access to prostate-specific antigen testing and mortality among men with prostate cancer","volume":"7","author":"Iyer","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ctarc.2026.101336_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2024.03.018","article-title":"Prostate radiotherapy in low-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis","author":"Roy","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ctarc.2026.101336_bib0006","first-page":"15","article-title":"Focal therapy for prostate cancer: recent advances and insights","author":"Lasorsa","year":"2025","journal-title":"Curr. Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101336_bib0007","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.21037\/tau-23-667","article-title":"Risk factors for secondary bladder cancer following prostate cancer radiotherapy","volume":"13","author":"Jahrei\u00df","year":"2024","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.ctarc.2026.101336_bib0008","article-title":"Enhancing androgen deprivation therapy (ADT) integration in prostate cancer: insights for stereotactic body radiotherapy (SBRT) and brachytherapy modalities","volume":"45","author":"Gomez-Iturriaga","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101336_bib0009","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.eururo.2023.11.018","article-title":"Prostate-specific membrane antigen\u2013Targeted therapies for Prostate cancer: towards improving therapeutic outcomes","volume":"85","author":"Corpetti","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ctarc.2026.101336_bib0010","first-page":"1","article-title":"Quality of information and appropriateness of open AI outputs for prostate cancer","author":"Lombardo","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101336_bib0011","doi-asserted-by":"crossref","first-page":"200","DOI":"10.62347\/JSAE9732","article-title":"Artificial intelligence in pathologic diagnosis, prognosis and prediction of prostate cancer","volume":"12","author":"Zhu","year":"2024","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"10.1016\/j.ctarc.2026.101336_bib0012","article-title":"Identification of cancer stem cell-related genes through single cells and machine learning for predicting prostate cancer prognosis and immunotherapy","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2026.101336_bib0013","doi-asserted-by":"crossref","DOI":"10.1177\/15330338241290029","article-title":"Advancements in biomarkers of prostate cancer: a review","volume":"23","author":"Agbetuyi-Tayo","year":"2024","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2026.101336_bib0014","series-title":"Urologic Oncology: Seminars and Original Investigations","first-page":"159.e17","article-title":"Different diagnostic strategies combining prostate health index and magnetic resonance imaging for predicting prostate cancer: A multicentre study","author":"Zhu","year":"2024"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101336_bib0015","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.ijrobp.2024.02.014","article-title":"A phase 1 trial of salvage stereotactic body radiation therapy for radiorecurrent prostate cancer after brachytherapy","volume":"119","author":"Patel","year":"2024","journal-title":"Int. J. Radiat. Oncol.* Biol.* Phys."},{"key":"10.1016\/j.ctarc.2026.101336_bib0016","series-title":"Stereotactic Ablative Radiotherapy (SAbR) for Primary Prostate Cancer, Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy: A Comprehensive Guide","first-page":"293","author":"Desai","year":"2024"},{"key":"10.1016\/j.ctarc.2026.101336_bib0017","series-title":"Seminars in Oncology","article-title":"Efficacy of metformin drug in preventing metabolic syndrome associated with androgen deprivation therapy (ADT) in prostate cancer patients: a systematic review and meta-analysis","author":"Yakout","year":"2024"},{"issue":"10442","key":"10.1016\/j.ctarc.2026.101336_bib0018","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(24)00549-X","article-title":"Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101336_bib0019","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1007\/s12094-024-03508-2","article-title":"Prostate cancer biomarkers: from early diagnosis to precision treatment","volume":"26","author":"Dahiya","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ctarc.2026.101336_bib0020","first-page":"1","article-title":"High interobserver variability of PTEN immunohistochemistry defining PTEN status in low-to intermediate-risk prostate cancer: results of the first German ring trial","author":"Hommerding","year":"2024","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ctarc.2026.101336_bib0021","series-title":"Systematic Review and Meta-Analysis of the Diagnostic Performance of Stockholm3: A Methodological Evaluation","author":"Heiter","year":"2024"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101336_bib0022","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3348\/kjr.2024.1024","article-title":"Prostate cancer screening with MRI: lessons learned from repeat rounds of the G\u00d6TEBORG-2 and STHLM3-MRI trials","volume":"25","author":"Woo","year":"2024","journal-title":"Korean J. Radiol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101336_bib0023","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","article-title":"Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial","volume":"22","author":"Nordstr\u00f6m","year":"2021","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.ctarc.2026.101336_bib0024","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.3390\/cancers13133373","article-title":"Prostate cancer liquid biopsy biomarkers\u2019 clinical utility in diagnosis and prognosis","volume":"13","author":"Matuszczak","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101336_bib0025","article-title":"Urinary PCA3 a superior diagnostic biomarker for prostate cancer among Ghanaian men","volume":"2022","author":"Opoku Mensah","year":"2022","journal-title":"Dis. Markers"},{"key":"10.1016\/j.ctarc.2026.101336_bib0026","doi-asserted-by":"crossref","DOI":"10.1177\/17562872221103988","article-title":"Biomarkers for prostate cancer detection and risk stratification","volume":"14","author":"Farha","year":"2022","journal-title":"Ther. Adv. Urol."},{"key":"10.1016\/j.ctarc.2026.101336_bib0027","article-title":"Etiology of prostate cancer with the TMPRSS2: ERG fusion: a systematic review of risk factors","author":"McGrath","year":"2024","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101336_bib0028","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.3390\/ijms24032185","article-title":"Biomarkers of aggressive prostate cancer at diagnosis","volume":"24","author":"Boehm","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101336_bib0029","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3390\/ijms18020473","article-title":"Current insights into long non-coding RNAs (LncRNAs) in prostate cancer","volume":"18","author":"Smolle","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101336_bib0030","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41588-020-0648-8","article-title":"The DNA methylation landscape of advanced prostate cancer","volume":"52","author":"Zhao","year":"2020","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101336_bib0031","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/biom7010015","article-title":"The genomic impact of DNA CpG methylation on gene expression; relationships in prostate cancer","volume":"7","author":"Long","year":"2017","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101336_bib0032","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1158\/1078-0432.CCR-18-2847","article-title":"Validation of melanoma immune profile (MIP), a prognostic immune gene prediction score for stage II\u2013III melanoma","volume":"25","author":"Gartrell","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101336_bib0033","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","article-title":"Epidemiology and prevention of prostate cancer","volume":"4","author":"Gandaglia","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.ctarc.2026.101336_bib0034","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-1-0716-1354-2_9","article-title":"PCA3 in prostate cancer","author":"Gunelli","year":"2021","journal-title":"Urin. Biomark.: Methods Protoc."},{"key":"10.1016\/j.ctarc.2026.101336_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.06.006","article-title":"Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance","volume":"518","author":"Jamroze","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ctarc.2026.101336_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2020.104669","article-title":"Covid-19 pathogenesis in prostatic cancer and TMPRSS2-ERG regulatory genetic pathway, infection","volume":"88","author":"Afshari","year":"2021","journal-title":"Genet. Evol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101336_bib0037","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3390\/clinpract14020039","article-title":"Tissue-based genomic testing in prostate cancer: 10-year analysis of national trends on the use of Prolaris, Decipher, ProMark, and Oncotype DX","volume":"14","author":"Bologna","year":"2024","journal-title":"Clin. Pract."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101336_bib0038","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","article-title":"A systematic review of the evidence for the decipher genomic classifier in prostate cancer","volume":"79","author":"Jairath","year":"2021","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101336_bib0039","article-title":"A 4K score\/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer","volume":"4","author":"Wagaskar","year":"2021","journal-title":"Cancer Rep."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101336_bib0040","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.3390\/ijms22115515","article-title":"AR-V7 in metastatic prostate cancer: a strategy beyond redemption","volume":"22","author":"Sobhani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101336_bib0041","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41585-021-00497-7","article-title":"Salvage therapy for prostate cancer after radical prostatectomy","volume":"18","author":"Zaorsky","year":"2021","journal-title":"Nat. Rev. Urol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101336_bib0042","doi-asserted-by":"crossref","first-page":"54","DOI":"10.21037\/cco-24-52","article-title":"Advancements in artificial intelligence for robotic-assisted radical prostatectomy in men suffering from prostate cancer: results from a scoping review","volume":"13","author":"Castellani","year":"2024","journal-title":"Chin. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101336_bib0043","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1016\/j.pec.2022.04.017","article-title":"Communication, perception, and use of personalized side-effect risks in prostate cancer treatment-decision making: an observational and interview study","volume":"105","author":"Vromans","year":"2022","journal-title":"Patient Educ. Couns."},{"key":"10.1016\/j.ctarc.2026.101336_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejon.2021.101913","article-title":"Effect of Kegel exercises on the prevention of urinary and fecal incontinence in patients with prostate cancer undergoing radiotherapy","volume":"51","author":"Urvayl\u0131o\u011flu","year":"2021","journal-title":"Eur. J. Oncol. Nurs."},{"key":"10.1016\/j.ctarc.2026.101336_bib0045","first-page":"87","article-title":"Evolution of androgen deprivation therapy (ADT) and its new emerging modalities in prostate cancer: an update for practicing urologists, clinicians and medical providers","author":"Choi","year":"2022","journal-title":"Res. Rep. Urol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101336_bib0046","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/pros.24519","article-title":"Adverse metabolic consequences of androgen deprivation therapy (ADT) on Asian patients with prostate cancer: primary results from the real-life experience of ADT in Asia (READT) study","volume":"83","author":"Wong","year":"2023","journal-title":"Prostate"},{"issue":"S1","key":"10.1016\/j.ctarc.2026.101336_bib0047","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1089\/end.2017.0723","article-title":"Robot-assisted radical prostatectomy: a step-by-step guide","volume":"32","author":"Huynh","year":"2018","journal-title":"J. Endourol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101336_bib0048","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17050902","article-title":"Recent Advances in radical prostatectomy: a narrative review of surgical innovations and outcomes","volume":"17","author":"Jo","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101336_bib0049","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ijrobp.2019.09.044","article-title":"External beam radiation therapy (EBRT) and high-dose-rate (HDR) brachytherapy for intermediate and high-risk prostate cancer: the impact of EBRT volume","volume":"106","author":"Tharmalingam","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101336_bib0050","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.brachy.2025.06.005","article-title":"High-dose-rate (HDR) brachytherapy boost in combination with external beam radiotherapy for localized prostate cancer: an evidence-based consensus statement","volume":"24","author":"Patel","year":"2025","journal-title":"Brachytherapy"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101336_bib0051","article-title":"Androgen deprivation therapy for prostate cancer: focus on cognitive function and mood","volume":"60","author":"Reiss","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101336_bib0052","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","article-title":"Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations","volume":"22","author":"Crawford","year":"2019","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.ctarc.2026.101336_bib0053","series-title":"A Perspective From the GU Editorial Team","first-page":"1114","article-title":"Photons, protons, SBRT, brachytherapy\u2014what is leading the charge for the management of prostate cancer?","author":"Choudhury","year":"2021"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101336_bib0054","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.3390\/cancers14092226","article-title":"Stereotactic radiation therapy versus brachytherapy: relative strengths of two highly efficient options for the treatment of localized prostate cancer","volume":"14","author":"Kissel","year":"2022","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101336_bib0055","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101336_bib0056","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijrobp.2021.07.1714","article-title":"Dose-based radiomic analysis (dosiomics) for intensity modulated radiation therapy in patients with prostate cancer: correlation between planned dose distribution and biochemical failure","volume":"112","author":"Murakami","year":"2022","journal-title":"Int. J. Radiat. Oncol.* Biol.* Phys."},{"issue":"14","key":"10.1016\/j.ctarc.2026.101336_bib0057","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.3390\/cancers14143484","article-title":"A prospective study of stereotactic body radiotherapy (SBRT) with concomitant whole-pelvic radiotherapy (WPRT) for high-risk localized prostate cancer patients using 1.5 tesla magnetic resonance guidance: the preliminary clinical outcome","volume":"14","author":"Poon","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101336_bib0058","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.ijrobp.2021.01.043","article-title":"A pooled toxicity analysis of moderately hypofractionated proton beam therapy and intensity modulated radiation therapy in early-stage prostate cancer patients","volume":"110","author":"Vapiwala","year":"2021","journal-title":"Int. J. Radiat. Oncol.* Biol.* Phys."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101336_bib0059","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1016\/j.prro.2023.06.004","article-title":"Long-term outcomes of a prospective study on highly hypofractionated intensity modulated radiation therapy for localized prostate cancer for 3 weeks","volume":"13","author":"Nakamura","year":"2023","journal-title":"Pract. Radiat. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101336_bib0060","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00345-023-04380-5","article-title":"External beam radiotherapy combination is a risk factor for bladder cancer in patients with prostate cancer treated with brachytherapy","volume":"41","author":"Minami","year":"2023","journal-title":"World J. Urol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101336_bib0061","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3390\/jpm14080882","article-title":"Outcomes of I-125 low-dose-rate brachytherapy in patients with localized prostate cancer: a comprehensive analysis from a specialized tertiary referral center","volume":"14","author":"Schubert","year":"2024","journal-title":"J. Pers. Med."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101336_bib0062","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/curroncol32060360","article-title":"Dosimetric comparison of VMAT alone and VMAT with HDR brachytherapy boost using clinical and biological dose models in localized prostate cancer","volume":"32","author":"Guhlich","year":"2025","journal-title":"Curr. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101336_bib0063","article-title":"Normal tissue integral dose as a result of prostate radiation therapy: a quantitative comparison between high-dose-rate brachytherapy and modern external beam radiation therapy techniques","volume":"8","author":"Grzywacz","year":"2023","journal-title":"Adv. Radiat. Oncol."},{"key":"10.1016\/j.ctarc.2026.101336_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102206","article-title":"Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: an ESTRO ACROP Delphi consensus","volume":"98","author":"Jereczek-Fossa","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101336_bib0065","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3390\/life12050711","article-title":"SBRT for localized prostate cancer: CyberKnife vs. VMAT-FFF, a dosimetric study","volume":"12","author":"Serra","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.ctarc.2026.101336_bib0066","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1007\/s00432-021-03785-2","article-title":"Five-year outcomes of stereotactic body radiation therapy (SBRT) for prostate cancer: the largest experience in China","volume":"147","author":"Zhao","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101336_bib0067","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.clgc.2020.08.002","article-title":"Metastasis-directed therapy (SBRT) guided by PET-CT 18F-CHOLINE versus PET-CT 68Ga-PSMA in castration-sensitive oligorecurrent prostate cancer: a comparative analysis of effectiveness","volume":"19","author":"Mazzola","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101336_bib0068","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.ijrobp.2020.11.003","article-title":"Biochemical control and toxicity outcomes of stereotactic body radiation therapy versus low-dose-rate brachytherapy in the treatment of low-and intermediate-risk prostate cancer","volume":"109","author":"Gogineni","year":"2021","journal-title":"Int. J. Radiat. Oncol.* Biol.* Phys."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101336_bib0069","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-068580","article-title":"Reirradiation options for previously irradiated prostate cancer (RO-PIP): feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT)","volume":"12","author":"Zhong","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.ctarc.2026.101336_bib0070","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1240939","article-title":"Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes","volume":"13","author":"Carrasquilla","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2026.101336_bib0071","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.704664","article-title":"The influence of miRNAs on radiotherapy treatment in prostate cancer\u2013a systematic review","volume":"11","author":"Soares","year":"2021","journal-title":"Front. Oncol."},{"issue":"17","key":"10.1016\/j.ctarc.2026.101336_bib0072","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101336_bib0073","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00259-020-05025-0","article-title":"PET\/MRI in prostate cancer: a systematic review and meta-analysis","volume":"48","author":"Evangelista","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101336_bib0074","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13550-023-00984-5","article-title":"Detecting localised prostate cancer using radiomic features in PSMA PET and multiparametric MRI for biologically targeted radiation therapy","volume":"13","author":"Chan","year":"2023","journal-title":"EJNMMI Res."},{"issue":"10288","key":"10.1016\/j.ctarc.2026.101336_bib0075","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(21)00581-X","article-title":"18F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomised controlled trial","volume":"397","author":"Jani","year":"2021","journal-title":"The Lancet"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101336_bib0076","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41585-022-00618-w","article-title":"The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer","volume":"19","author":"Wang","year":"2022","journal-title":"Nat. Rev. Urol."},{"issue":"1131","key":"10.1016\/j.ctarc.2026.101336_bib0077","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210728","article-title":"Prostate-specific membrane antigen (PSMA) fusion imaging in prostate cancer: PET\u2013CT vs PET\u2013MRI","volume":"95","author":"Liu","year":"2022","journal-title":"Br. J. Radiol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101336_bib0078","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.ijrobp.2020.12.020","article-title":"Hypofractionated radiation therapy to the prostate bed with intensity-modulated radiation therapy (IMRT): a phase 2 trial","volume":"109","author":"Leite","year":"2021","journal-title":"Int. J. Radiat. Oncol.* Biol.* Phys."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101336_bib0079","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/jamaoncol.2023.1638","article-title":"Comparing risk for second primary cancers after intensity-modulated vs 3-dimensional conformal radiation therapy for prostate cancer, 2002-2015","volume":"9","author":"Pithadia","year":"2023","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101336_bib0080","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ijrobp.2022.12.008","article-title":"Long-term results of a phase 3 randomized prospective trial of erectile tissue-sparing intensity-modulated radiation therapy for men with clinically localized prostate cancer","volume":"115","author":"Zhang","year":"2023","journal-title":"Int. J. Radiat. Oncol.* Biol.* Phys."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101336_bib0081","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41391-023-00684-0","article-title":"Artificial intelligence applications in prostate cancer","volume":"27","author":"Baydoun","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101336_bib0082","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1470-2045(24)00220-1","article-title":"Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study","volume":"25","author":"Saha","year":"2024","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101336_bib0083","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/curroncol32010015","article-title":"Focal therapy for prostate cancer: recent advances and insights","volume":"32","author":"Lasorsa","year":"2025","journal-title":"Curr. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101336_bib0084","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3390\/diagnostics16091310","article-title":"Beyond one-size-fits-all active surveillance for low-risk prostate cancer: risk-adapted follow-up, de-escalation pathways, and focal therapy as tailored strategy","volume":"16","author":"Zattoni","year":"2026","journal-title":"Diagnostics"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101336_bib0085","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1038\/s41598-022-09120-0","article-title":"Comparison of toxicities between ultrahypofractionated radiotherapy versus brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer","volume":"12","author":"Yamazaki","year":"2022","journal-title":"Sci. Rep."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:53:59Z","timestamp":1790913239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226002479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":85,"alternative-id":["S2468294226002479"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101336","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiotherapy strategies for prostate cancer: Techniques, outcomes, and patient care","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101336","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101336"}}